This threshold was reduced twice; between 2016 and 2017 and from 2018 onwards, only patients with confirmed < 25% and < 20% biotinidase activity, respectively, were started on biotin treatment (15–20 mg/day for profound BD and 5–10 mg/day for the partial BD). The gene discussed is BTD; the disease is Behcet disease.